Analysis of TP53 gene mutations in human lung cancer: Comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing

https://doi.org/10.1016/j.cdp.2005.10.004Get rights and content

Abstract

Introduction: Automated capillary electrophoresis single strand conformation polymorphism (CE-SSCP), denaturant gradient gel electrophoresis (DGGE), and direct sequencing were compared to investigate the benefits and sensitivity of each of the methods for detection of unknown TP53 mutations in human lung cancer. Methods: Twenty previously analyzed DNA samples from lung tumors were examined under dummy laboratory codes for occurrence of mutations of the TP53 gene. Results: Mutations were found in 17 samples; 15 (88%) of them were detected by DGGE, 16 (94%) by CE-SSCP and 12 (71%) by direct sequencing. One of the two mutations that remained undetected in DGGE was in fact outside the sequence area covered by DGGE screening, thus rendering DGGE and CE-SSCP equally efficient in mutation detection. Direct sequencing performed less well in finding mutations than the two other assays, as also shown previously. Conclusion: The study showed that CE-SSCP is a fast and highly reproducible method, which is considerably less laborious compared to DGGE, for screening of unknown TP53 mutations.

Introduction

The tumor suppressor gene TP53 is one the most studied genes in cancer research. The p53 protein mediates many different cellular processes that control cell growth, including effects on cell cycle, DNA repair, apoptosis, differentiation and angiogenesis [1]. It plays a central role in the cell's response to various kinds of stress situations, including damage to DNA. Mutation of the TP53-gene is the most common genetic alteration in the human cancers [2], [3]. TP53 is a fairly large gene, and mutations discovered in human cancer are scattered all over the 10 encoding exons. Still, majority of the mutations occur in exons 5–8, which is the conserved area of the gene. Mutations of the TP53 gene are typically of diverse types, including base substitutions, small deletions, and insertions [4]. Therefore, investigation of human tumor DNAs for presence of unknown mutations must rely on an efficient screening system with high sensitivity.

Various methods based on gel electrophoresis have traditionally been used in mutation detection to separate the wildtype sequence from the mutated ones. The methods based on gel separation are simple to run and do not require large investments in equipment. Denaturant gradient gel electrophoresis (DGGE) and single strand conformation polymorphism (SSCP) are both commonly used methods for mutation screening. They enable rather quick and reliable detection of variations in DNA sequence, but neither of them provides information about the type or exact location of the variation. Generally, DGGE is considered to be more sensitive than the standard SSCP assay [5], whereas the latter is considered simpler to run. These methods are, however, typically time consuming and they cannot be easily automated. Application of the capillary electrophoresis (CE) technique, among other fairly recently developed methods such as denaturing high performance liquid chromatography (DHPLC), has made it possible to achieve faster analysis and greater automation [6], [7]. With the use of CE technique, SSCP has become more readily applicable for investigating large collections of DNA samples [8]. Ultimately, for identification of the alterations detected in screening, the DNA fragments must be sequenced.

In the present study, capillary electrophoresis SSCP (CE-SSCP) was compared with the traditional slab gel DGGE, and direct sequencing to find out the benefits and relative sensitivities of the three methods for detection of somatic mutations of the TP53 gene in human tumor samples.

Section snippets

Tumor samples and DNA extraction

Twenty lung cancer samples were analysed for TP53 mutations. DNA samples were prepared from fresh lung tumor specimens from which non-tumor tissue was carefully excluded macroscopically by pathologist before storage at −80 °C, as described earlier [9]. For the present work, new DNAs were prepared from samples cut from the same tumor tissue specimens, except for the cases for which DNA samples but no tumor specimens were available (samples # T174, T182, T213, T246, and T316). The DNA was purified

Results

In the present analysis, altogether 17 out of 20 samples of the lung tumor DNA analyzed were found to carry a mutation. For three tumors, the mutation discovered in the previous analyses was not detected by any of the assays used. Since new DNA needed to be extracted from the tissue specimens for the present work, it may be that the newly cut tissue sections did not contain large enough proportions of the mutated cells to appear positive in the analysis. Of the total of 17 mutations, 15 were

Discussion

In the present study, all the mutation detection methods used were able to recognize the majority of the pre-known TP53 mutations present in the lung tumors examined. CE-SSCP assay had a high efficacy in detecting mutations (16 out of 17, 94%), DGGE assay detected one mutation less than CE-SSCP, but the mutation was situated in the intronic area and was thus not properly within the area efficiently screened with DGGE. Even though the sequences of the primers were the same for both of the

Acknowledgements

We thank Ms. Tuula Suitiala, chief technician, Finnish Institute of Occupational Health, Helsinki, for skillful technical assistance. The work was financially supported by the EU 5th FP project no. QLK4-2000-00573 (WOOD-RISK).

References (17)

There are more references available in the full text version of this article.

Cited by (21)

  • Mutation screening of the BRCA1 gene in sporadic breast cancer in the Central of Iran

    2018, Meta Gene
    Citation Excerpt :

    It enables rather quick and reliable detection of variations in DNA sequence, but does not provide information about the type or exact location of the variation. Generally, for identification of the alterations detected in screening, the DNA fragments must be sequenced (Holmila and Husgafvel-Pursiainen, 2006). Experimental determination of gene alternations is tedious and costly.

  • Fluorescence coupled in-capillary DNA hybridization assay and its application to identification of DNA point mutation

    2016, Sensors and Actuators, B: Chemical
    Citation Excerpt :

    CE-based mutation detection technologies are well represented by single-stranded conformation polymorphism analysis (CE-SSCP) and restriction fragment length polymorphism analysis (CE-RFLP). Holmila et al. [33] have used CE-SSCP assay to analyze the TP53 gene point mutations in human lung cancer specimens, and have found that the sensitivity and accuracy of the assay are comparable with that being derived from DNA gel electrophoresis. Shin et al. [34] have established a bacterial pathogen detection system based on CE-SSCP technique, which could simultaneously detect 8 bacterial pathogens in clinical settings.

  • Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study

    2008, Blood
    Citation Excerpt :

    The performance of each method was validated on cell lines with known TP53 mutations before use of the method in the study of DLBCL tumors.33,38-40 Several studies have shown equivalent performance (90%-100% concordance) in mutation detection accuracy between DGGE and SSCP and between DGGE and dHPLC.38-40 No significant false-positive rate has been observed (eg, disproportionate G-A change), and confirmatory sequencing after each screening method would mitigate any false-positive results.

  • Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods

    2020, Hematology, Transfusion and Cell Therapy
    Citation Excerpt :

    Recently, ibrutinib, idelalisib and venetoclax, which inhibits the Bruton tyrosine kinase (BTK), the phosphatidylinositol 3-kinase (PI3K) and BCL2, respectively, have been approved, based on their efficacy in CLL clinical trials with patients harboring del17p/TP53 mutations.10 The p53 protein is a crucial transcription factor for the cell because it controls several biological processes, such as cell cycle, differentiation, DNA repair, apoptosis and angiogenesis.18 Defects in the p53 pathway prevent DNA repair and apoptosis, resulting in genomic instability and abnormal cell proliferation.18

View all citing articles on Scopus
View full text